AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34847501 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone ISM® 75 or 100 mg once-monthly intramuscular injections for 12 months
Number of subjects: 215
Study 34411756 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dark ink tattoos
Number of subjects: 34
Study 34411756 — intervention group
Group type: COMPARATOR
Intervention: UV ink tattoos
Number of subjects: 34
Study 34412109 — intervention group
Group type: EXPERIMENTAL
Intervention: THC + CBD
Number of subjects: 18
Study 34412109 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD
Number of subjects: 18
Study 34412109 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 18
Study 34412109 — intervention group
Group type: COMPARATOR
Intervention: THC
Number of subjects: 18
Study 33023494 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis implementation intervention
Number of subjects: 0
Study 35509348 — intervention group
Group type: COMPARATOR
Intervention: gLiFE (group-based LiFE)
Number of subjects: 252
Study 35509348 — intervention group
Group type: COMPARATOR
Intervention: LiFE (individually delivered LiFE)
Number of subjects: 252
Study 34586227 — intervention group
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation with ranibizumab injections
Number of subjects: 30
Study 34586227 — intervention group
Group type: COMPARATOR
Intervention: Panretinal photocoagulation alone
Number of subjects: 30
Study 36056918 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of dietary diversity questions earlier in the interview
Number of subjects: 0
Study 36056918 — intervention group
Group type: COMPARATOR
Intervention: Placement of dietary diversity questions later in the interview
Number of subjects: 0
Study 34858651 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise (PRE), three 40‐min sessions per week for 12 weeks
Number of subjects: 91
Study 34858651 — intervention group
Group type: COMPARATOR
Intervention: Control group (non‐exercise group)
Number of subjects: 91
Study 35127941 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Number of subjects: 50
Study 35127941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 32559716 — intervention group
Group type: EXPERIMENTAL
Intervention: digital CBTI
Number of subjects: 91
Study 32559716 — intervention group
Group type: COMPARATOR
Intervention: digital sleep education control
Number of subjects: 91
Study 34505954 — intervention group
Group type: EXPERIMENTAL
Intervention: Magmaris stent
Number of subjects: 50
Study 34505954 — intervention group
Group type: COMPARATOR
Intervention: Xience stent
Number of subjects: 50
Study 33913639 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g)
Number of subjects: 4431
Study 33913639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4431
Study 33979366 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear growth (length for age z score, LAZ)
Number of subjects: 0
Study 33979366 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation at home
Number of subjects: 0
Study 33979366 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of diarrhoeal episodes
Number of subjects: 0
Study 33979366 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight for height z scores (WHZ)
Number of subjects: 0
Study 33979366 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth order
Number of subjects: 0
Study 36096333 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed self-sampling kit
Number of subjects: 93
Study 36096333 — intervention group
Group type: COMPARATOR
Intervention: Clinic screening
Number of subjects: 93
Study 33845034 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin 2.0 mg/kg intravenously once every 3 weeks until disease progression or unacceptable toxicity
Number of subjects: 102
Study 33845034 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin
Number of subjects: 102
Study 36113394 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline or interpersonal psychotherapy for 14 weeks (T2)
Number of subjects: 58
Study 36113394 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment received (Sertraline or interpersonal psychotherapy)
Number of subjects: 58
Study 36113394 — intervention group
Group type: COMPARATOR
Intervention: Control group (female controls)
Number of subjects: 58
Study 35016413 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention including a whole‐process escort playing a relative role combined with mind mapping
Number of subjects: 256
Study 35016413 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing intervention (Control)
Number of subjects: 256
Study 33258790 — intervention group
Group type: EXPERIMENTAL
Intervention: myCompass (eMH program)
Number of subjects: 780
Study 33258790 — intervention group
Group type: COMPARATOR
Intervention: Healthy Lifestyles (attention control)
Number of subjects: 780
Study 33258790 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (myCompass and Healthy Lifestyles)
Number of subjects: 780
Study 33964979 — intervention group
Group type: EXPERIMENTAL
Intervention: Online reciprocal imitation training (RIT)
Number of subjects: 20
Study 33964979 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 20
Study 32695652 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Qigong (TCQ)
Number of subjects: 50
Study 32695652 — intervention group
Group type: COMPARATOR
Intervention: Control group (meeting class once a week for 12 weeks)
Number of subjects: 50
Study 33500235 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockwave therapy
Number of subjects: 60
Study 33500235 — intervention group
Group type: COMPARATOR
Intervention: Ureteroscopy
Number of subjects: 60
Study 34212560 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine plus intravenous remifentanil (DEX-REMI group)
Number of subjects: 40
Study 34212560 — intervention group
Group type: COMPARATOR
Intervention: Intravenous remifentanil only (REM group)
Number of subjects: 40
Study 35289848 — intervention group
Group type: EXPERIMENTAL
Intervention: Karydakis flap surgery
Number of subjects: 125
Study 35289848 — intervention group
Group type: COMPARATOR
Intervention: Excision and suture in the midline
Number of subjects: 125
Study 33664086 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide for 3 months
Number of subjects: 38
Study 33187978 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 131
Study 33187978 — intervention group
Group type: COMPARATOR
Intervention: Interferon-α2
Number of subjects: 131
Study 35350988 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan + Shenfu injection (SFI)
Number of subjects: 101
Study 35350988 — intervention group
Group type: COMPARATOR
Intervention: Levosimendan
Number of subjects: 101
Study 35350988 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan + SFI
Number of subjects: 101
Study 33823265 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity intermittent negative pressure (INP) of -40 mm Hg for one hour twice daily for 24 weeks
Number of subjects: 10
Study 32347365 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Number of subjects: 38
Study 32347365 — intervention group
Group type: COMPARATOR
Intervention: Control group without IORT
Number of subjects: 38
Study 35573387 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated intervention combining CBT4CBT and Recovery Coaching
Number of subjects: 0
Study 35573387 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 0
Study 33871363 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture (L. plantarum PBS067, L. reuteri PBS072, L. rhamnosus LRH020) for 56 days
Number of subjects: 80
Study 33871363 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 56 days
Number of subjects: 80
Study 36040071 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B gel (LAmB gel) for 28 days
Number of subjects: 13
Study 36040071 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel for 28 days
Number of subjects: 13
Study 36040071 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B gel (LAmB gel) for 56 days
Number of subjects: 13
Study 36040071 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients at 56 days
Number of subjects: 13
Study 33540112 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied offline over right DLPFC
Number of subjects: 0
Study 33540112 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied offline over left PPC
Number of subjects: 0
Study 33540112 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied offline over right PPC
Number of subjects: 0
Study 33540112 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied offline over left DLPFC
Number of subjects: 0
Study 33540112 — intervention group
Group type: EXPERIMENTAL
Intervention: Online tDCS (various loci)
Number of subjects: 0
Study 33000366 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent theta-burst stimulation (iTBS)
Number of subjects: 28
Study 33000366 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 28
Study 32707917 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 h fasting duration
Number of subjects: 24
Study 32707917 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 h fasting duration
Number of subjects: 24
Study 32707917 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 h fasting duration
Number of subjects: 24
Study 36071664 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet for multimodal learning
Number of subjects: 80
Study 36071664 — intervention group
Group type: COMPARATOR
Intervention: Nurse explanation on home self‐injection of enoxaparin sodium (Control)
Number of subjects: 80
Study 32889626 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 40
Study 32889626 — intervention group
Group type: COMPARATOR
Intervention: sEMG
Number of subjects: 40
Study 32864755 — intervention group
Group type: EXPERIMENTAL
Intervention: Body imagery rescripting
Number of subjects: 130
Study 32864755 — intervention group
Group type: EXPERIMENTAL
Intervention: General imagery rescripting
Number of subjects: 130
Study 32864755 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 130
Study 32864755 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 130
Study 34554879 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain acceptance
Number of subjects: 187
Study 33787151 — intervention group
Group type: EXPERIMENTAL
Intervention: Yangxue Qingnao Granules combined with conventional anti-hypertensive agents
Number of subjects: 4532
Study 34862359 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS) applied to the injured left-hemispheric cortex for 1-3 weeks
Number of subjects: 0
Study 34862359 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (Tx0) for 3 weeks
Number of subjects: 0
Study 33054008 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional conservative therapy and different wavelengths laser therapy (LT) course
Number of subjects: 102
Study 33054008 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional conservative therapy and intravenous laser blood irradiation (ILBI) (λ - 635 nm)
Number of subjects: 102
Study 33054008 — intervention group
Group type: COMPARATOR
Intervention: Traditional conservative therapy only
Number of subjects: 102
Study 36289532 — intervention group
Group type: COMPARATOR
Intervention: 7 + 3
Number of subjects: 0
Study 34839884 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodynamic resuscitation with Ringer lactate (20mL·kg‐1) and norepinephrine initiated 3h after sepsis induction
Number of subjects: 18
Study 34839884 — intervention group
Group type: COMPARATOR
Intervention: Control group (SHAM)
Number of subjects: 18
Study 34839884 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis group without hemodynamic resuscitation (ETX‐NR)
Number of subjects: 18
Study 36388664 — intervention group
Group type: COMPARATOR
Intervention: Group B (FiO2 =0.6, PEEP =5 cmH2O)
Number of subjects: 120
Study 36388664 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (FiO2 =1.0, PEEP =10 cmH2O)
Number of subjects: 120
Study 36388664 — intervention group
Group type: COMPARATOR
Intervention: Group A (FiO2 =0.6, PEEP =0)
Number of subjects: 120
Study 36388664 — intervention group
Group type: COMPARATOR
Intervention: Group C (FiO2 =1.0, PEEP =8 cmH2O)
Number of subjects: 120
Study 32028927 — intervention group
Group type: EXPERIMENTAL
Intervention: My Joint Pain website (users)
Number of subjects: 277
Study 32028927 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-users)
Number of subjects: 277
Study 35710594 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0
Study 35710594 — intervention group
Group type: EXPERIMENTAL
Intervention: Established antihypertensive therapy
Number of subjects: 0
Study 35710594 — intervention group
Group type: EXPERIMENTAL
Intervention: Change to a regimen compatible with pregnancy
Number of subjects: 0
Study 33221789 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge and attitudes about cancer and its risk factors
Number of subjects: 1200
Study 35649128 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid wrist-hand orthosis worn ≥6 hours per night for 3 years
Number of subjects: 74
Study 35649128 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual multidisciplinary care)
Number of subjects: 74
Study 35730245 — intervention group
Group type: EXPERIMENTAL
Intervention: EsoduoⓇ (esomeprazole 20 mg with sodium bicarbonate 800 mg)
Number of subjects: 379
Study 35730245 — intervention group
Group type: COMPARATOR
Intervention: NexiumⓇ (esomeprazole 20 mg)
Number of subjects: 379
Study 34124929 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Cognitive Processing Therapy (CPT)
Number of subjects: 254
Study 34124929 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Processing Therapy (CPT)
Number of subjects: 254
Study 32414888 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block (post‐tetanic count 1 or 2)
Number of subjects: 58
Study 32414888 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular block (train‐of‐four 1 or 2)
Number of subjects: 58
Study 32414888 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Number of subjects: 58
Study 32414888 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular block
Number of subjects: 58
Study 35417957 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hemodilution (hematocrit maintained >25%)
Number of subjects: 186
Study 35417957 — intervention group
Group type: COMPARATOR
Intervention: Moderate hemodilution (hematocrit maintained within 21-25%)
Number of subjects: 186
Study 33952531 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated damage from induced earthquakes
Number of subjects: 3934
Study 32198939 — intervention group
Group type: EXPERIMENTAL
Intervention: Branebrutinib (0.3-30 mg for SAD; 0.3-10 mg for JMAD)
Number of subjects: 96
Study 32198939 — intervention group
Group type: EXPERIMENTAL
Intervention: Branebrutinib (daily for 14 days in MAD)
Number of subjects: 96
Study 32198939 — intervention group
Group type: EXPERIMENTAL
Intervention: Branebrutinib (single 10 mg dose)
Number of subjects: 96
Study 32198939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 35869266 — intervention group
Group type: EXPERIMENTAL
Intervention: Momelotinib
Number of subjects: 0
Study 35869266 — intervention group
Group type: COMPARATOR
Intervention: Ruxolitinib then momelotinib
Number of subjects: 0
Study 35869266 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy then momelotinib
Number of subjects: 0
Study 35869266 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline transfusion independence (TI)
Number of subjects: 0
Study 35869266 — intervention group
Group type: EXPERIMENTAL
Intervention: Week 24 TI response in JAKi-naïve, momelotinib-randomized patients
Number of subjects: 0
Study 32158202 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT) - 9-week program, twice a week
Number of subjects: 40
Study 32158202 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - attended disease lectures
Number of subjects: 40
Study 36116766 — intervention group
Group type: EXPERIMENTAL
Intervention: QST-derived sensory phenotype 'sensory loss'
Number of subjects: 133
Study 36116766 — intervention group
Group type: EXPERIMENTAL
Intervention: QST-derived sensory phenotype 'mechanical hyperalgesia'
Number of subjects: 133
Study 34397698 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Naikan therapy (NT) and Morita therapy (MT) for 7 consecutive weeks
Number of subjects: 130
Study 34397698 — intervention group
Group type: COMPARATOR
Intervention: Normal medical treatments without NT and MT
Number of subjects: 130
Study 32776533 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% atropine with orthokeratology (AOK)
Number of subjects: 59
Study 32776533 — intervention group
Group type: COMPARATOR
Intervention: Ortho-k only (OK)
Number of subjects: 59
Study 36173238 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-only configuration of the iLet® bionic pancreas (BP)
Number of subjects: 90
Study 32515894 — intervention group
Group type: EXPERIMENTAL
Intervention: GreenLight HPS laser 120 W (PVP)
Number of subjects: 153
Study 32515894 — intervention group
Group type: COMPARATOR
Intervention: Diode laser 300 W (CVP)
Number of subjects: 153
Study 32515894 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 153
Study 32502564 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) sessions (3 sessions of 20 minutes each over 3 consecutive days)
Number of subjects: 24
Study 32502564 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) sessions (group 1, n=10)
Number of subjects: 24
Study 32502564 — intervention group
Group type: COMPARATOR
Intervention: Control condition (regular rehabilitation practice over a week)
Number of subjects: 24
Study 35969979 — intervention group
Group type: EXPERIMENTAL
Intervention: Video interviews
Number of subjects: 0
Study 35969979 — intervention group
Group type: COMPARATOR
Intervention: In-person interviews
Number of subjects: 0
Study 33238718 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-informed intervention program (The Incredible Explorers, 6-week program)
Number of subjects: 61
Study 33238718 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting to receive the intervention)
Number of subjects: 61
Study 32585997 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotics
Number of subjects: 58
Study 32585997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 35337193 — intervention group
Group type: EXPERIMENTAL
Intervention: Development and Well-Being Assessment (DAWBA) as an adjunct to referral letters
Number of subjects: 160
Study 35337193 — intervention group
Group type: COMPARATOR
Intervention: Standard referral letters without DAWBA
Number of subjects: 160
Study 32418785 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI radiomics based on enhanced T1WI images
Number of subjects: 98
Study 35805311 — intervention group
Group type: EXPERIMENTAL
Intervention: Partly structured activity group (N = 62)
Number of subjects: 145
Study 35805311 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-play group (N = 43)
Number of subjects: 145
Study 35805311 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 36)
Number of subjects: 145
Study 35486044 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure without balloon sizing
Number of subjects: 381
Study 35486044 — intervention group
Group type: COMPARATOR
Intervention: Closure using balloon sizing
Number of subjects: 381
Study 616714877 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 42
Study 616714877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 35461285 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisecretory factor (Salovum®) as a food supplement
Number of subjects: 100
Study 35461285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 32659919 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-Free meal (GF)
Number of subjects: 11
Study 32659919 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Food meal (WF)
Number of subjects: 11
Study 32659919 — intervention group
Group type: COMPARATOR
Intervention: Processed Food meal (PF)
Number of subjects: 11
Study 33596852 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry beverage consumed daily for 24 weeks
Number of subjects: 0
Study 33596852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33596852 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry beverage
Number of subjects: 0
Study 33047325 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping with and Caring for Infants with Special Needs (COPCA)
Number of subjects: 16
Study 33047325 — intervention group
Group type: COMPARATOR
Intervention: Standard infant physiotherapy
Number of subjects: 16
Study 32037483 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer‐mediated intervention (PMI) for children with ASD
Number of subjects: 65
Study 35013866 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 and omega-6 fatty acid supplementation
Number of subjects: 100
Study 35013866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 32513257 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Timoptic-XE® (timolol maleate ophthalmic gel forming solution)
Number of subjects: 0
Study 32513257 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) plus hydrogel (placebo)
Number of subjects: 0
Study 35340222 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signatures based on preoperative F-FDG PET/CT
Number of subjects: 120
Study 33840651 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial interventions focusing on exercise, nutrition, social participation, and improvement of mental health.
Number of subjects: 9754
Study 33576591 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional burnout syndrome
Number of subjects: 378
Study 33576591 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroticism
Number of subjects: 378
Study 36202911 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambling-like rewards (loot box)
Number of subjects: 153